Management of Breathlessness with High-flow Nasal Therapy or a Fan

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-26

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Airflow directed to the face by a fan is shown to relief breathlessness in palliative care and some studies have suggested High-Flow nasal airflow therapy beneficial as well. However, these two treatments have not been compared.

40 patients with advanced cancer and breathlessness are recruited from Tampere University Hospital or Pirkanmaa Hospice. All patients are treated with two therapies: 1. High-Flow nasal airflow therapy with a nasal cannula and 2. airflow directed to the face by a fan. Both treatment periods last 30 minutes or as long as the patient wish to use the therapy. The effects of the therapies on breathlessness are compared by asking the subjective relief of breathlessness after each therapies. The study do not limit any other therapies used in the normal clinical care for the patients. Thus, all the other therapies the physicians taking care of the patient orders are permitted. Hopefully, the patients achieve relief for their breathlessness through the study treatments given in addition to their normal treatment. There are no significant risks related to the therapies, but they may cause some inconveniences such as mouth dryness. These possible side-effects of the therapies are asked as well.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Use of a Handheld Fan to Manage Breathlessness - A Feasibility Study

NCT00974558

Dyspnea

COMPLETED NA

Effects of Treatment With High Flow Nasal Cannulas on Respiratory Pattern and Work of Breathing Among Healthy Subjects

NCT02495675

Respiratory Failure

UNKNOWN NA

Effects of Long-term Dry and Humidified Low-flow Oxygen Via Nasal Cannula

NCT02515786

Chronic Respiratory Failure

UNKNOWN PHASE1/PHASE2

Pilot Study of Physiological Effect of High-Flow Nasal Cannula on Respiratory Pattern and Work of Breathing

NCT02514798

COPD

COMPLETED NA

Novel Respiratory Training as Part of Palliative Care for Older Adults With Heart Failure

NCT06576297

Aging Heart Failure With Preserved Ejection Fraction Heart Failure With Reduced Ejection Fraction +3 more

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Airflow directed to the face by a fan is shown to relief breathlessness in palliative care and some studies have suggested High-Flow nasal airflow therapy beneficial as well. However, these two treatments have not been compared and High-Flow nasal airflow therapy has not been tested in the context of hospice.

40 patients over 18 years with advanced cancer and breathlessness are recruited from Tampere University Hospital or Pirkanmaa Hospice. All patients are treated with two therapies: 1. High-Flow nasal airflow therapy with a nasal cannula and 2. airflow directed to the face by a fan (crossover trial). Both treatment periods last 30 minutes or as long as the patient wish to use the therapy. The effects of the therapies on breathlessness are compared by asking the subjective relief of breathlessness after each therapies with numeric rating scale (NRS) from 0 (no breathlessness) to 10 (the worst possible breathlessness). Influence of the treatments on anxiety, pain and mouth dryness are measured as well with numeric rating scale (NRS) from 0 to 10. The study do not limit any other therapies used in the normal clinical care for the patients. Thus, all the other therapies the physicians taking care of the patient orders are permitted. Hopefully, the patients achieve relief for their breathlessness through the study treatments given in addition to their normal treatment. There are no significant risks related to the therapies, but they may cause some inconveniences such as mouth dryness. These possible side-effects of the therapies are asked as well.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breathlessness Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fan first

Patients use the fan first and high-flow nasal therapy thereafter

Group Type ACTIVE_COMPARATOR

High-flow nasal therapy

Intervention Type DEVICE

A high-flow nasal therapy for 30 minutes.

Airflow directed to face by a fan

Intervention Type DEVICE

A fan directed to the face for 30 minutes

High-flow nasal therapy first

Patients use high-flow nasal therapy first and the fan thereafter

Group Type ACTIVE_COMPARATOR

High-flow nasal therapy

Intervention Type DEVICE

A high-flow nasal therapy for 30 minutes.

Airflow directed to face by a fan

Intervention Type DEVICE

A fan directed to the face for 30 minutes

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

High-flow nasal therapy

A high-flow nasal therapy for 30 minutes.

Intervention Type DEVICE

Airflow directed to face by a fan

A fan directed to the face for 30 minutes

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Advanced cancer
* At least 18 years of age
* Breathlessness (At least 3 on a NRS-scale from 0 to 10)
* Capable to understand the study and to give informed consent
* Do not benefit from ICU treatment or resuscitation defined by the physician taking care of the patient

Exclusion Criteria

* Insufficient co-operation for the study treatment or to give informed consent
* Oxygen saturation under 88 % on room air
* Need for other device to treat the breathlessness
* The reason of breathlessness can be immediately treated

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No